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Background: The clinical utility of molecular profiling of tumor tissue to guide treatment of patients with advanced
solid tumors is unknown. Our objectives were to evaluate the frequency of genomic alterations, clinical “actionability”
of somatic variants, enrollment in mutation-targeted or other clinical trials, and outcome of molecular profiling for
advanced solid tumor patients at the Princess Margaret Cancer Centre (PM).
Methods: Patients with advanced solid tumors aged ≥18 years, good performance status, and archival tumor tissue
available were prospectively consented. DNA from archival formalin-fixed paraffin-embedded tumor tissue was tested
using a MALDI-TOF MS hotspot panel or a targeted next generation sequencing (NGS) panel. Somatic variants were
classified according to clinical actionability and an annotated report included in the electronic medical record.
Oncologists were provided with summary tables of their patients’ molecular profiling results and available mutation-
specific clinical trials. Enrolment in genotype-matched versus genotype-unmatched clinical trials following release of
profiling results and response by RECIST v1.1 criteria were evaluated.
Results: From March 2012 to July 2014, 1893 patients were enrolled and 1640 tested. After a median follow-up of
18 months, 245 patients (15 %) who were tested were subsequently treated on 277 therapeutic clinical trials, including
84 patients (5 %) on 89 genotype-matched trials. The overall response rate was higher in patients treated on genotype-
matched trials (19 %) compared with genotype-unmatched trials (9 %; p < 0.026). In a multi-variable model, trial
matching by genotype (p = 0.021) and female gender (p = 0.034) were the only factors associated with increased
likelihood of treatment response.
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Conclusions: Few advanced solid tumor patients enrolled in a prospective institutional molecular profiling trial were
treated subsequently on genotype-matched therapeutic trials. In this non-randomized comparison, genotype-
enrichment of early phase clinical trials was associated with an increased objective tumor response rate.
Trial registration: NCT01505400 (date of registration 4 January 2012).
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Molecular profiling can provide diagnostic, prognostic,
or treatment-related information to guide cancer patient
management. Advances in next-generation sequencing
(NGS) have enabled multiplex testing to overcome the
constraints associated with sequential single-analyte test-
ing [1–3]. Large-scale research projects have elucidated
genomic landscapes of many cancers but have provided
limited insight into the clinical utility of genomic testing.
Our aim was to evaluate if targeted DNA profiling im-
proves outcomes for patients assigned to clinical trials
based on knowledge of actionable somatic mutations.
At the Princess Margaret Cancer Centre (PM), the
Integrated Molecular Profiling in Advanced Cancers
Trial (IMPACT) and Community Molecular Profiling
in Advanced Cancers Trial (COMPACT) are prospect-
ive studies that provide molecular characterization data
to oncologists to match patients with advanced solid
tumors to clinical trials with targeted therapies. Here,
we report the frequency of alterations, clinical “action-
ability” of the somatic variants, clinical trial enrollment,
and outcome based upon molecular profiling results.
Methods
Patient cohort
For IMPACT, patients with advanced solid tumors treated
at PM were prospectively consented for molecular profil-
ing during a routine clinical visit. For COMPACT, patients
with advanced solid tumors treated at other hospitals in
Ontario were referred to a dedicated weekly clinic at
PM for eligibility review, consent, and blood sample
collection. Eligible patients had advanced solid tumors,
were aged ≥18 years, had Eastern Cooperative Oncology
Group (ECOG) performance status ≤1, and had available
formalin-fixed paraffin-embedded (FFPE) archival tumor
tissue. The University Health Network Research Ethics
Board approved this study (#11-0962-CE). Enrollment for
IMPACT began on 1 March 2012 and for COMPACT on
16 November 2012 and ended on 31 July 2014 for this
analysis.
Specimens
DNA was extracted from sections of FFPE tumor speci-
mens from biopsies or surgical resections. If multiple
archival tumor specimens were available, the most recentarchival FFPE specimen was reviewed, with a minimum
acceptable tumor cellularity of 10 %. Tumor regions
were isolated by 1–2 × 1 mm punch from FFPE blocks
or manual macrodissection of unstained material from
15–20 slides. FFPE samples were deparaffinized, cells
lysed with proteinase K, and DNA extracted using the
QIAmp DNA FFPE Tissue Kit (Qiagen, Germantown,
MD, USA). DNA was quantified using the Qubit dsDNA
Assay kit on the Qubit 2.0 Fluorometer (ThermoFisher
Scientific, Waltham, MA, USA).
Participants provided a peripheral blood sample (5 mL
in EDTA-coated tubes) as a source of matched germline
DNA. DNA was extracted using either standard manual
phenol/chloroform extraction methods or automated ex-
traction (MagAttract DNA Mini M48 kit; Qiagen). Pa-
tients were offered return of pathogenic germline results
at the time of consent and asked to identify a family mem-
ber delegate who could receive results on their behalf if
required.
Molecular profiling assays
All testing was performed in a laboratory accredited by
the College of American Pathologists (CAP) and certified
to meet Clinical Laboratory Improvement Amendments
(CLIA). Three molecular profiling assays were used over
the study period: a custom multiplex genotyping panel on
a matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass-spectrometry platform (MassAR-
RAY, Agena Bioscience, San Diego, CA, USA) to genotype
279 mutations within 23 genes (Additional file 1: Table
S1); the TruSeq Amplicon Cancer Panel (TSACP, Illu-
mina) on the MiSeq sequencer (Illumina) covering regions
of 48 genes (Additional file 1: Table S2); and the Ion
AmpliSeq Cancer Panel (ASCP, ThermoFisher Scientific)
on the Ion Proton sequencer (ThermoFisher Scientific)
covering regions of 50 genes (Additional file 1: Table S3).
For more in-depth methodology on molecular profiling
assays, including sequence alignment and base calling, see
Additional file 1: Supplementary Methods.
Variant assessment and classification
Variants were assessed and classified according to the
classification scheme of Sukhai et al. [4]. Briefly, a five-
class scheme was used to sort variants according to action-
ability (defined as providing information on prognosis,
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ants in specific tumor sites, and known or predicted
deleterious effects on protein function. Interpretation
and data integration were performed using Alamut v.2.4.5
(Interactive Biosoftware, Rouen, France). Primary review,
assessment, and classification of all variants were inde-
pendently performed by a minimum of two assessors
followed by a third review prior to reporting, with cases
where assessors disagreed resolved by group discussion.
Immunohistochemistry (IHC)
Phosphatase and tensin homolog (PTEN) IHC was per-
formed using rabbit monoclonal Ab 138G6 (Cell Signaling
Technology, Danvers, MA, USA) on a Dako platform
using a dilution of 1:50 and Flex + 30 protocol. Complete
absence of tumor cell staining with positive staining of
surrounding tumor stroma fibroblasts/endothelial cells
was used to denote PTEN deficiency [5].
Return of testing results
The molecular profiling report was included in the
electronic medical record and returned to the treating
oncologist. The clinical significance of profiling results
was discussed with PM patients during a routine clinic
visit by their treating oncologist. A PM oncologist
reviewed results with patients treated at other hospitals
by telephone. All oncologists were provided with regular
summary tables of testing results and mutation-specific
clinical trial listings available at PM. A monthly genomic
tumor board was convened at PM to establish consensus
treatment recommendations for patients with complex
profiling results. A committee consisting of a molecular
geneticist, medical geneticist, genetic councilor, and med-
ical oncologist reviewed pathogenic germline variants be-
fore return of germline testing results. Germline results
were disclosed to the patient or designate by a genetic
counselor or medical geneticist.
Clinical data collection
For each patient, baseline patient and tumor characteris-
tics, treatment regimen(s), time on treatment(s) and sur-
vival were retrieved from medical records and updated
every three months. Therapeutic clinical trial enrollment
was evaluated from the date of reporting molecular pro-
filing results until 9 January 2015. Genotype-matched
trials were defined as studies with eligibility criteria re-
stricted to patients with specific somatic mutations,
those with a targeted drug with enriched clinical or pre-
clinical activity in a patient’s genotype, or those with a
drug that inhibited a pathway directly linked to the
somatic mutation. Decisions about trial enrollment
were based upon trial availability, patient or physician
preference, and did not follow a pre-specified algorithm.Targeted lesion measurements and RECIST 1.1 [6] assess-
ments were performed by radiologists.
Statistics
Descriptive statistics were used to summarize patient
characteristics, profiling results, and anti-tumor activ-
ity. Comparisons between patients with profiling results
treated on genotype-matched and genotype-unmatched
trials were performed using a generalized estimating
equation (GEE) model [7]. A multi-variable GEE model
for response included trial matching by genotype, gender,
trial phase, number of lines of prior systemic therapy, in-
vestigational agent class, age, tumor type, and sequencing
platform. A mixed model was used to compare time on
treatment, defined as the date of trial enrollment until the
date of discontinuation of investigational treatment. A ro-
bust score test was used to compare overall survival
following trial enrolment between genotype-matched and
genotype-unmatched groups [8]. These comparisons
accounted for individual patients who were included on
multiple therapeutic trials [8]. Differences with p values of
< 0.05 were considered statistically significant.
Results
Patient cohort
A total of 1893 patients were enrolled, including
gynecological (23 %), breast (18 %), lung (18 %), colo-
rectal (17 %), pancreatobiliary (8 %), upper aerodigestive
(6 %), genitourinary (5 %), and other (5 %) cancers
(Table 1). The median age was 59 years (age range, 18–89
years); patients were predominantly female (69 %); had
received a median of 2 prior systemic treatments (range,
1–18), and had excellent performance status (43 % PS0
and 56 % PS1). Of 253 (13 %) screen failures, 10 % were
for insufficient tissue or DNA and 3 % for clinical deteri-
oration or other reasons. The median follow-up from
reporting results was 18 months (range, 1–33 months). A
total of 651 (40 %) patients were deceased at the time of
the database lock.
Molecular profiling
Successful molecular profiling was achieved in 1640
patients (87 %), 827 (50 %) had samples tested by
MALDI-TOF MS, 792 (48 %) by TSACP, and 21 (1 %)
by ASCP (Fig. 1). One or more somatic mutations were
detected in 341 (41 %) patients tested by MALDI-TOF
MS, 583 (74 %) by TSACP, and 14 (67 %) by ASCP.
Median laboratory turnaround time (sample receipt to
report) was 32 days (range, 6–228 days). Of patient sam-
ples tested by MALDI-TOF MS, KRAS (21 %) was the
most frequently mutated gene, followed by PIK3CA
(12 %), with additional genes in the range of 1–5 %
frequency. Of samples tested by the TSACP, TP53 had
the highest mutation frequency (47 % of all identified
Table 1 Characteristics of patients enrolled into IMPACT/COMPACT (n = 1893)
Patients enrolled Patients enrolled Patients profiled Patients profiled enrolled on
any therapeutic trials
Patients profiled enrolled on
genotype-matched trials
Median age (range) 59 (18–89) 58 (18–89) 58 (18–81) 58 (24–81)
Female/Male 1303/590 (59 %)/(31 %) 1166/479 (71 %)/(29 %) 205/72 (74 %)/(26 %) 64/25 (72 %)/(28 %)
Median lines of prior treatment (range) 2 (1–18) 2 (1–18) 2 (1–16) 2 (1–11)
ECOG performance status (0/1/2) 43 %/56 %/<1 % 44 %/55 %/<1 % 78 %/22 %/0 % 78 %/22 %/0 %
Median time from collection of archival tumor sample to
profiling report in years (range)
1.6 (0.1-24.9) 1.7 (0.1-18.9) 1.9 (0.1-18.9)
Primary lesion/Metastatic lesion profiled 1080/560 193/84 66/23
(66 %)/(34 %) (70 %)/(30 %) (74 %)/(26 %)
Tumor types
Breast 341 (18 %) 310 (19 %) 41/310 (13 %) 19/310 (6 %)
Colorectal 326 (17 %) 299 (18 %) 38/299 (13 %) 18/299 (6 %)
Gynecological 430 (23 %) 405 (25 %) 80/405 (20 %) 20/405 (5 %)
Lung 339 (18 %) 256 (16 %) 43/256 (17 %) 18/256 (7 %)
Genitourinary 92 (5 %) 74 (5 %) 9/74 (12 %) 4/74 (5 %)
Pancreatobiliary 151 (8 %) 104 (6 %) 9/104 (9 %) 1/104 (1 %)
Upper aerodigestive 115 (6 %) 102 (6 %) 8/102 (8 %) 2/102 (2 %)
Other 99 (5 %) 81 (5 %) 17/81 (21 %) 2/81 (2 %)
TOTAL 1893 1640 245/1640 (15 %) 84/1640 (5 %)
Fig. 1 CONSORT diagram
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mutation frequencies in the range of 5–15 % and the
remainder <5 % (Fig. 2). We attribute the difference in
mutation landscape between these two platforms to
inclusion of TP53 in the TSACP assay but not in
MALDI-TOF (see Additional file 1: Supplemental
Methods).
Class 1 and 2 variants are the most clinically significant
with known actionability for the specific variant in the
tumor site tested (Class 1) or a different tumor site (Class
2) [4]. More than 20 % of patients with breast, colorectal,
gynecologial, lung, or pancreatobiliary cancers had Class 1
or 2 variants detected by TSACP or MALDI-TOF (Fig. 3).
Of patients with genitourinary cancers, only 9 % had
actionable variants identified on TSACP and 3 % on
MALDI-TOF. For patients with other solid tumors, 25 %
had actionable variants identified on TSACP and 18 % on
MALDI-TOF. PTEN protein expression was lost by IHCa
b
Fig. 2 Mutation frequency by gene from results of (a) MALDI-TOF, n = 827,
was calculated as number of variant occurrences within each gene dividedfor 122/788 (15 %) tumors tested. PTEN gene mutations
were detected by NGS in 14/122 (11.5 %) tumors that
were PTEN-negative by IHC.
Clinical trials and outcomes
Of the 1640 patients with molecular profiling results,
245 (15 %) were subsequently enrolled in 277 thera-
peutic clinical trials, including 84 (5 %) treated on 89
genotype-matched trials (Table 2). Patients with pan-
creatobiliary, upper aerodigestive tract, and other solid
tumors were least likely to be treated on genotype-
matched trials. Somatic mutations in four genes
(PIK3CA, KRAS, BRAF, and EGFR) accounted for 76/89
(85 %) of genotype-matched trial enrollments: including
PIK3CA for breast cancer (20/22); BRAF (5/18) and
KRAS (9/18) for colorectal cancer; KRAS (9/18) and
EGFR (7/18) for non-small cell lung cancer; and KRAS
(14/22) and PIK3CA (7/22) for gynecological cancers. Aand (b) TruSeq Amplicon Cancer Panel, n = 792. Mutation frequency
by the total number of patients
a c
b d
Fig. 3 Distribution of patients by tumor site and most actionable variant identified [4]. Cases tested with TruSeq Amplicon Cancer Panel (TSACP;
n = 792) are shown in (a) and (b); cases tested by MALDI-TOF MS (n = 827) are shown in (c) and (d). a Proportion and number of variants by
tumor site, TSACP. b Actionability of variants by tumor site, TSACP. c Proportion and number of variants by tumor site, MALDI-TOF. d Actionability
of variants per case by tumor site, MALDI-TOF. Patients with more than one variant were counted once by their most actionable variant class.
Total number of patients is indicated by value within or below each bar section. “Gyne-other” includes cervical, endometrial, fallopian tube,
uterine, and vulvar
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drug class, somatic genotype (variant level), and tumor
type are summarized in Table 3.
The age and sex distribution, as well as the number of
lines of prior systemic therapy, were similar between the
genotype-matched and genotype-unmatched trial patient
cohorts (Table 2). There was no difference in the propor-
tion of trials that were genotype-matched between pa-
tients profiled on MALDI-TOF MS (61/176 [35 %])
compared with TSACP (28/101 [28 %]; p = 0.24). A higher
proportion of genotype-matched trial patients were
treated in phase I studies (81 %) compared with genotype-
unmatched trials (46 %; p < 0.001). Genotype-matched
trial patients were more likely to be treated with targeted
drug combinations without chemotherapy or immuno-
therapy. The overall response rate was higher in patients
treated on genotype-matched trials (19 %) compared with
genotype-unmatched trials (9 %; p = 0.026) (Fig. 4). Inmulti-variable analysis, trial matching according to geno-
type (p = 0.021) and female gender (p = 0.034) were the
only statistically significant factors associated with re-
sponse (Additional file 1: Table S4). Genotype-matched
trial patients were more likely to achieve a best response
of any shrinkage in the sum of their target lesions (62 %)
compared with genotype-unmatched trial patients (32 %;
p < 0.001). There was no difference in the time on treat-
ment (15 months versus 15 months; p = 0.12) or overall
survival (16 months versus 13 months; p = 0.10) for pa-
tients treated on genotype-matched versus genotype-
unmatched trials.
Germline testing
Of the patients who were asked during consent about
return of incidental pathogenic germline mutations, 658/
698 (94.3 %) indicated that they wished to receive these
results. Two patients were identified with TP53 variants







Median age (range) 58 (18–81) 58 (24–81) 58.5 (18–80) NS
Female/Male 205/72 64/25 141/47 NS
Median prior systemic
therapies (range)
2 (1–16) 2 (1–11) 2 (1–16) NS
Tumor type (number of patients)
Breast 47 22 25 NS
Colorectal 43 18 25
Lung 48 18 30
Gynecological 91 22 69
Other 48 9 39
Genotyping platform (number of patients)







Trial phase (number of patients)
Phase I 158 72 86 <0.001
Phase II 67 9 58
Phase III 52 8 44
Investigational agent(s) (number of patients)
Targeted
monotherapy







Immunotherapy 34 0 34
Radiotherapy 1 0 1
NS not significant
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36-year-old woman diagnosed with metastatic breast
cancer, with a prior papillary thyroid cancer at the age of
28 years, who had a heterozygous germline TP53
c.817C > T (p.Arg273Cys) pathogenic mutation. Her
family history was notable for her mother who died from
cancer of unknown primary at the age of 63 years and a
maternal aunt with breast cancer at the age of 62 years.
The second patient, a 77-year-old woman diagnosed
with metastatic cholangiocarcinoma, had no family his-
tory of malignancy. We detected a heterozygous TP53
c.524G > A (p.Arg175His) pathogenic mutation at 15 %
allele frequency in the blood that was not present in
tumor. This finding is not consistent with inherited Li-
Fraumeni syndrome (LFS), but may represent either
clonal mosaicism or an age-related or treatment-related
mutation limited to blood.Discussion
We demonstrated that molecular profiling with mass-
spectrometry-based genotyping or targeted NGS can
be implemented in a large academic cancer center to
identify patients with advanced solid tumors who are
candidates for genotype-matched clinical trials. The
rapid enrolment to our study reflects the high level of
motivation of patients and their oncologists to pursue
genomic testing that has been previously reported by
our group [9, 10] and others [1, 11–13]. Disappoint-
ingly, only 5 % of patients who underwent successful
molecular profiling in our study were subsequently
treated on genotype-matched clinical trials, consistent
with other centers. For comparison, the MD Anderson
institutional genomic testing protocol matched 83/
2000 (4 %) of patients [1], the SAFIR-01 breast cancer
trial matched 28/423 (7 %) [14], and the British
Columbia Cancer Agency Personalized Oncogenomics
Trial matched 1/100 (1 %) [15]. To facilitate trial accrual,
we incorporated multidisciplinary tumor board discus-
sions, physician-directed email alerts with genotype-
matched trial listings available at our institution, and indi-
vidual physician summaries of profiling results. In spite of
these efforts, the rate of genotype-matched clinical trial
enrolment was low, due to patient deterioration, lack of
available clinical trials, and unwillingness of patients to
travel for clinical trial participation. There was no differ-
ence in proportion of patients treated on genotype-
matched trials who underwent profiling using MALDI-
TOF or a larger targeted NGS panel. This highlights how
few somatic mutations are truly “druggable” through clin-
ical trial matching, even in a large academic cancer center
with a broad portfolio of phase I/II trials.
A key finding of our study is that patients in genotype-
matched trials were more likely to achieve response than
patients in genotype-unmatched trials. Albeit a non-
randomized comparison, this finding comprises an import-
ant metric and distinguishes our molecular profiling
program from other prospective studies that have not
tracked longitudinal clinical outcome [1, 16, 17]. Von
Hoff and colleagues were the first to report clinical
outcome from a prospective molecular profiling (MP)
study, with 18/66 (27 %) of patients who received treat-
ment guided by MP data, including RNA-expression
profiling and immunohistochemistry (IHC) or fluores-
cence in situ hybridization (FISH) testing for 11 markers,
achieving a progression-free survival (PFS) ratio on MP-
selected therapy/PFS on prior therapy) of ≥ 1.3 [18]. This
study was performed prior to the era of multiplex muta-
tion testing and many patients received MP-guided ther-
apy with cytotoxic therapy using biomarker data that has
not been shown to influence treatment response. An
analysis of 1114 patients treated on investigational clinical
trials at the Clinical Center for Targeted Therapy at MD
Table 3 Genotype-matched clinical trials by drug class, somatic
genotypes (variant level), and tumor type (n = 89)









Breast PIK3CA E545K PI3K, Endocrine −90 %
Colorectal BRAF V600E BRAF, PI3K, EGFR −85 %
Colorectal BRAF V600E BRAF, PI3K, EGFR −81 %
TP53 S215G
Gynecological KRAS G13D PI3K, MEK −70 %
Gynecological PIK3CA H1047R VEGF −64 %
KRAS G12D
Gynecological KRAS G12V PI3K, MEK −63 %
Breast PIK3CA H1047R PI3K, IGF1R −61 %
Lung EGFR E746_A750del EGFR −58 %
EGFR T790M
Lung KRAS G13D MEK −54 %
Breast PIK3CA H1047R PI3K −50 %
Lung EGFR L858R EGFR −47 %
EGFR T790M
CTNNB1 S37C
Gynecological KRAS G12D MEK −47 %
Gynecological KRAS G12V PI3K, IGF1R −45 %
NRAS Q61R
Gynecological KRAS G12A PI3K, MEK −38 %
Breast PIK3CA N345K ANG2, MTOR −37 %
Lung KRAS G12D PI3K, MEK −37 %
Gynecological PIK3CA H1047R PI3K, MEK −37 %
KRAS G12D
Lung KRAS G12C MEK −28 %
Gynecological TP53 K132N WEE1 −26 %
Gynecological KRAS G12D PI3K, MEK −25 %








BRAF V600E MEK −20 %
Lung KRAS G12S MEK −20 %
Gynecological KRAS G12D MEK, PI3K −20 %
Colorectal BRAF V600E BRAF, PI3K, EGFR −20 %
TP53 R175H
TP53 Q165X
Breast FGFR2 Y376C FGFR −19 %
Breast PIK3CA H1047L PI3K −18 %
Table 3 Genotype-matched clinical trials by drug class, somatic
genotypes (variant level), and tumor type (n = 89) (Continued)
Other GNAQ Q209P MEK −18 %
Lung EGFR L858R HER3, EGFR −18 %
Lung KRAS G12A PI3K, MEK −17 %
Lung EGFR L858R HER3, EGFR −17 %
Colorectal KRAS G12D PI3K, MEK −16 %
PIK3CA E545K
Gynecological KRAS G12V PI3K, MEK −16 %
Gynecological BRAF V600E MEK −15 %
Gynecological KRAS G12D PI3K, MEK −15 %
Lung KRAS G12V PI3K, MEK −13 %
Colorectal KRAS G12S MEK, EGFR −13 %
Gynecological NRAS Q61K PI3K, MEK −13 %
Pancreatobiliary KRAS G12V PI3K, IGF1R −13 %
Gynecological PIK3CA H1047R ANG2, mTOR −9 %
Breast PIK3CA E545K AKT −7 %
Colorectal KRAS G12V MEK, EGFR −7 %
Breast ERBB2 D769H PI3K, IGF1R −7 %
PIK3CA N345K
Lung KRAS G12V MEK −6 %




Genitourinary No mutations PI3K −5 %
PTEN negative
on IHC
Lung EGFR L858R EGFR −4 %
Lung EGFR L858R EGFR −4 %
Lung EGFR E746_A750del EGFR −3 %
Breast PIK3CA H1047R AKT −3 %
Upper
aerodigestive
KRAS G12V PI3K, MEK −2 %
Gynecological KRAS G12D PI3K, MEK −2 %
Colorectal KRAS G13D MEK, EGFR −0.6 %
Genitourinary No mutations PI3K 0 %
PTEN negative
on IHC
Breast PIK3CA H1047R PI3K 0 %




MEK, EGFR +2 %
Colorectal KRAS G13D PI3K, MEK +2 %
PIK3CA E545K
Breast PIK3CA H1047L PI3K, IGF1R +4 %
Genitourinary No mutations PI3K +4 %
Stockley et al. Genome Medicine  (2016) 8:109 Page 8 of 12
Table 3 Genotype-matched clinical trials by drug class, somatic
genotypes (variant level), and tumor type (n = 89) (Continued)
PTEN negative
on IHC
Gynecological PIK3CA E545K MTOR +5 %
Breast PIK3CA N345K PI3K, IGF1R +6 %
Breast PIK3CA N345K PI3K, MEK +6 %
NRAS G12D
Gynecological PIK3CA C420R FGFR, PI3K +8 %
Colorectal KRAS G12D MEK, EGFR +9 %
Lung PIK3CA E545K PI3K, IGF1R +11 %
Colorectal No mutations
(KRAS wildtype)
MEK, EGFR +11 %
Colorectal KRAS G12D PI3K, MEK +12 %
PIK3CA Q546K
Gynecological PIK3CA H1047R PI3K, IGF1R +12 %
Breast PIK3CA p.Glu545Gly AKT +28 %
PTEN p.Leu320X
PIK3CA p.Arg93Gln
Gynecological TP53 R175H PI3K +29 %
PIK3CA R93W
FBXW7 R479Q
Colorectal KRAS G12D PI3K, MEK +30 %
PIK3CA E545K
Genitourinary PIK3CA p.Asn345Lys PI3K +31 %
Breast PIK3CA E545K FGFR, PI3K +32 %
Breast PIK3CA H1047R PI3K, IGF1R +39 %
Colorectal No mutations
(KRAS wildtype)
MEK, EGFR +55 %
Breast PIK3CA E542K PI3K, Endocrine +66 %
Breast PIK3CA N345K PI3K, IGF1R NE
Lung KRAS G12C PI3K, MEK NE
Breast PIK3CA H1047R PI3K, IGF1R NE
Lung KRAS G12A MEK NE
PIK3CA H1047R
Gynecological KRAS G12A PI3K, IGF1R NE
Breast PIK3CA E545K PI3K NE
TP53 L252del
BRAF c.1315-4C > G
Gynecological KRAS G12V MEK NE
Lung BRAF V600E MEK NE
Breast PIK3CA H1047L PI3K NE
TP53 C238Y
Other KIT V559A PI3K, EGFR NE
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rate for patients with ≥1 molecular alteration treated
on trials with matched therapy was higher (27 %
versus 5 %, p < 0.0001) and the time to treatment fail-
ure was longer (5.2 versus 3.1 months; p < 0.0001)
than those who received non-matched therapy [19].
Limitations of this study were that some patients
underwent molecular testing after trial assignment and
different sequential molecular tests such as polymerase
chain reaction-based sequencing, IHC, and FISH, were
performed based upon the patient’s tumor type.
The same investigators from MD Anderson recently re-
ported the results of their prospective genomic profiling
study that enrolled 500 patients with advanced refractory
solid tumors assessed in their phase I program [20]. They
utilized the FoundationOne™ 236-gene targeted sequen-
cing panel and standard of care biomarker test results
(such as ER, PR, and HER2 IHC for breast cancer) to in-
form treatment selection for commercially available ther-
apies and clinical trial enrollment. A numerically higher
rate of prolonged disease control (complete response, par-
tial response, or stable disease ≥ 6 months) was observed
in patients who received matched therapy (122/500) com-
pared with those who received unmatched therapy (66/
500) (19 % versus 8 %, p = 0.061). Higher matching scores,
calculated based on the number of drug matches and
genomic aberrations per patient, were independently asso-
ciated with a greater frequency of prolonged disease con-
trol (22 % [high scores] versus 9 % [low scores], p = 0.024),
longer time-to-treatment failure (hazard ratio [HR] = 0.52,
95 % confidence interval [CI] = 0.36–0.74, p = 0.0003), and
survival (HR = 0.65, CI = 0.43–1.0, p = 0.05). Likewise, a
retrospective review of 347 consecutive patients with
advanced solid malignancies treated at the UC San Diego
Moores Cancer Center who had targeted sequencing
of archival tumor tissue using an earlier version of
Foundation One™ (182-gene panel) reported a higher
rate of disease control ≥ 6 months (34.5 %) for patients
(87/342) treated with matched therapy compared with
patients (93/342) treated with unmatched therapy
[21]. In both of these studies, the rate of treatment
matching (25 %) was significantly greater than our
study (5 %). This may be due to the use of larger gene
panels that include copy number alterations and re-
current translocations that may identify more “drug-
gable” alterations for matched therapy; analysis of
patient outcomes beyond therapeutic clinical trials
that included off-label treatment matching; and vary-
ing definitions of genomic alteration and treatment-
matching pairs. For instance, the UC San Diego
Moores matched therapy cohort included 11 patients
(13 %) with breast cancer who received endocrine
therapy based on ER expression and 11 patients (13 %)
with breast cancer who received HER2-directed
Fig. 4 a Waterfall plot of best tumor shrinkage of target lesions by RECIST for patients treated on (a) genotype-matched clinical trials (n = 79)
and (b) genotype-unmatched clinical trials (n = 150)
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ER and HER2 testing are routinely performed in
breast cancer patients to guide standard therapies,
these patients would not have been included in our
matched therapy cohort if the ER and HER2 status
were known prior to enrollment in our molecular
profiling study.
The only randomized trial that has prospectively
assessed the utility of molecular profiling (SHIVA) re-
ported no difference in objective response or PFS for
patients treated with genotype-matched versus standard
treatments [13]. More than 40 % of patients randomized
in the SHIVA trial did not have genomic alterations
identified and were included based upon expression of
hormone receptors. Patients were matched to a limited
range of approved targeted agents following a predefined
algorithm that did not include best-in-class investiga-
tional agents that are being tested in early phase clinical
trials. Despite the negative results of SHIVA, enthusiasmto conduct genomic-based clinical trials such as NCI-
MATCH [12] [NCT02465060], and LUNG-MAP [22]
[NCT02154490] remains strong to further define the
value of precision medicine. The findings of our
study, in which the majority of patients treated on
genotype-matched trials were enrolled in phase I
targeted therapy trials, are consistent with a recent
meta-analysis of phase I trials that demonstrated a
higher overall response rate (30.6 % versus 4.9 %,
p < 0.001) and median PFS (5.7 months versus
2.95 months, p < 0.001) for targeted therapy trials that
used biomarker-selection compared with those that
did not [23].
Measuring the clinical utility of molecular profiling is
difficult [3]. We did not comprehensively capture how
testing results influenced clinical decisions outside of
therapeutic clinical trial enrolment, such as reclassifica-
tion of tumor subtype and site of primary based on
mutation results. For example, we enrolled a patient
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metastases that was found to harbor a somatic IDH1
p.Arg132Cys variant, leading to the reclassification as a
likely intrahepatic cholangiocarcinoma. We also did not
fully evaluate the use of testing results to avoid ineffect-
ive standard treatments (i.e. KRAS exon 4 somatic vari-
ants in colorectal cancer to inform decision not to use
EGFR monoclonal antibody treatment) and treatment
with approved targeted agents outside of their approved
indications. Few patients in our study received targeted
treatments based upon profiling results outside of clinical
trials, due to limited access to targeted drugs outside of
publicly funded standard-of-care indications in Ontario.
New technological advances are being studied in mo-
lecular profiling programs—including larger gene panels
[2, 17]; whole exome [16], whole genome (WGS) or RNA
sequencing (RNA-Seq) [24, 25]; and integrative systems
biology analyses of deregulated cellular pathways [26].
Greater access to clinical trials for genomically character-
ized patients, such as umbrella and basket trial designs
[27], may also improve the success of genotype-treatment
matching. To assess whether decision support tools inte-
grated at the point of care can improve enrollment of pa-
tients on genotype-matched trials, we are piloting a smart
phone application to help physicians identify genotype-
matched trials for their patients with profiling data.
There are several limitations of our study. Only a
single archival sample was profiled for each patient,
often obtained many years prior to molecular testing.
Fresh biopsy of a current metastatic lesion for molecular
profiling at the time of study enrolment may have
yielded different results due to clonal evolution or tumor
heterogeneity [28]. Our genomic testing was limited to
hotspot point mutation testing or limited targeted se-
quencing and did not include gene copy number alter-
ations or recurrent translocations that may be important
for the selection of genotype-matched therapy. There
were patients identified with potentially “druggable” mu-
tations who were candidates for genotype-matched trials;
however, they could not be enrolled because of the con-
straints of slot allocation in early phase clinical trials
across multiple institutions or were deemed ineligible
due to trial-specific exclusion criteria. Our study popula-
tion also included many patients with heavily pre-treated
metastatic disease who were not well enough for further
therapy when results of molecular testing were reported.
In addition, tumor response is an imperfect surrogate end-
point to assess therapeutic benefit in early phase clinical
trials that should interpreted with caution [28]. We did
not observe a difference in time on treatment or overall
survival for patients treated on genotype-matched ver-
sus genotype-unmatched clinical trials. PFS data were
not available in our cohort precluding a comparison of
the outcome of genotype-matched therapy with theimmediate prior line of treatment, as has been reported
by other investigators [13, 14, 21].
Conclusions
We provide preliminary evidence that genotype-matched
trial treatment selected on the basis of molecular profil-
ing was associated with increased tumor shrinkage,
although only a small proportion of profiled patients
benefitted from this approach. Through this initiative,
we have created a valuable repository of data and tumor
samples that are amenable to additional research and
data sharing initiatives. Greater efforts should be made
to expand opportunities for genotype-trial matching and
further studies are needed to evaluate the clinical utility
of targeted NGS profiling.
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